Skip to main content

naproxen (Stirlescent®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name naproxen (Stirlescent®)
Formulation 250mg effervescent tablet
Reference number 3016
Indication

Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults

Company Stirling Anglian Pharmaceuticals Ltd
BNF chapter Musculoskeletal & joint diseases
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 26/01/2016
Follow AWTTC: